Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441675
Status:
COMPLETED
Last Update Posted:
2012-03-19
First Post:
2007-02-28
Brief Title:
A Long Term Prospective Follow Up Study For The CATO Study SAS30018SER9702
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Long Term Follow up Study for a Comparison of Stepwise Treatment of Asthmatic Children With SalmeterolFluticasone Propionate Combination Product SERETIDE andor Fluticasone Propionate FLIXOTIDE TM Based on PD20 Methacholine and Symptoms or Based on Symptoms Only
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The CATO population is a very well documented population during two years During this study patients were treated according to the CATO algorithm after that patient were treated according to the Dutch national GINA derived guidelines up to 6 years of follow-up The purpose of this prospective follow-up study is to understand the long-term effects of treatment Therefore the measurements done at baseline CATO part 1 are repeated after 6 years in this CATO-population CATO follow-up
Detailed Description:
A long term follow up study for a comparison of stepwise treatment of asthmatic children with SalmeterolFluticasone propionate combination product Seretide andor Fluticasone propionate Flixotide based on PD20 methacholine and symptoms or based on symptoms only Children Asthma Therapy Optimal
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None